Andrew J Cutler
Overview
Explore the profile of Andrew J Cutler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
1251
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kaul I, Claxton A, Sawchak S, Sauder C, Brannan S, Raj E, et al.
J Clin Psychiatry
. 2025 Mar;
86(1).
PMID: 40047530
To further characterize the safety and tolerability of oral xanomeline and trospium chloride in the treatment of people with schizophrenia experiencing acute psychosis. Pooled analyses were performed on safety data...
2.
Fava M, Pani L, De Martin S, Cutler A, Gorodetzky C, Vocci F, et al.
J Clin Psychiatry
. 2025 Feb;
86(1).
PMID: 39999772
Esmethadone is a novel -methyl-D-aspartate receptor (NMDAR) uncompetitive antagonist in development as adjunctive treatment for major depressive disorder (MDD). This 12-month, open-label study evaluated the safety and efficacy of esmethadone...
3.
4.
Correll C, Cutler A, Laliberte F, Germain G, MacKnight S, Boudreau J, et al.
Ann Gen Psychiatry
. 2025 Jan;
24(1):5.
PMID: 39871357
Background: Atypical antipsychotics are a common treatment for serious mental illness, but many are associated with adverse effects, including weight gain and cardiovascular issues, and real-world experience may differ from...
5.
Cutler A, Laliberte F, Germain G, MacKnight S, Boudreau J, Wade S, et al.
J Med Econ
. 2024 Nov;
27(1):1472-1484.
PMID: 39531329
Aims: To evaluate the healthcare resource utilization (HRU) and costs of patients who initiated cariprazine as their first versus subsequent atypical antipsychotic (AA) following a bipolar I disorder (BP-I) diagnosis....
6.
Childress A, Cutler A, Adler L, Fry N, Asubonteng K, Maldonado-Cruz Z, et al.
CNS Drugs
. 2024 Oct;
38(11):891-907.
PMID: 39373844
Background And Objective: Viloxazine ER (extended-release capsules; Qelbree) is a nonstimulant medication that has been approved by the United States Food and Drug Administration (FDA) for treatment of attention-deficit/hyperactivity disorder...
7.
Chepke C, Brunner E, Cutler A
Psychopharmacol Bull
. 2024 Sep;
54(4):45-80.
PMID: 39263202
Serotonin has been implicated in the neurobiology of attention-deficit/hyperactivity disorder (ADHD) due to its association with impulsivity, attention, and emotional regulation. Many compounds with serotonergic properties have been evaluated in...
8.
Fava M, Stahl S, Pani L, De Martin S, Cutler A, Maletic V, et al.
J Clin Psychiatry
. 2024 Jun;
85(3).
PMID: 38917366
To test esmethadone (REL-1017) as adjunctive treatment in patients with major depressive disorder (MDD) and inadequate response to standard antidepressants. In this phase 3, double-blind, placebo-controlled trial, outpatients with MDD...
9.
Cutler A, Kollins S, Brams M, Corliss M, Oh C, Braeckman R, et al.
Front Psychiatry
. 2024 Apr;
15:1310483.
PMID: 38566957
Objective: To evaluate treatment responder rate using the Attention-Deficit/Hyperactivity Disorder Rating Scale-5 (ADHD-RS-5) score based on optimized dose level of serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) and changes in ADHD severity in children (aged...
10.
Cutler A, Mattingly G, Kornstein S, Aaronson S, Lasser R, Zhang H, et al.
J Clin Psychiatry
. 2023 Dec;
85(1).
PMID: 38153320
Zuranolone is a positive allosteric modulator of both synaptic and extrasynaptic γ-aminobutyric acid (GABA) type A receptors and a neuroactive steroid approved in the United States as an oral, once-daily,...